Atlas Venture
Atlas Venture is a leading early-stage venture capital firm focused on investing in groundbreaking biotech innovation. With over 30 years of experience, Atlas Venture partners with top life science entrepreneurs to create and build breakthrough biotechnology companies. The firm is dedicated to translating groundbreaking science into life-changing medicines, having launched 70 startups from its incubator, with 25 medicines developed by its portfolio companies, 40 IPOs, and 34 M&A exits.
Atlas Venture
Portfolio
Nimbus Therapeutics received $4 billion upfront from Takeda for its TYK2 drug, marking one of the largest biotech licensing deals in recent years.
#Biotechnology
Korro Bio, an RNA editing startup, is expected to take its spot on the Nasdaq in the fourth quarter, having raised $117 million.
#Biotechnology
Eli Lilly will pay up to $1.925 billion for Versanis' weight loss drug, marking a significant acquisition in the biotech sector.
#Biotechnology
Mariana Oncology raised $175 million in a Series B round, focusing on developing radiopharmaceuticals.
#Radiopharmaceuticals
Intellia received FDA approval to start a phase 3 trial of its in vivo CRISPR-based gene editing therapy.
#Gene Editing
Q32 Bio will take Homology Medicines’ place on the Nasdaq to fund Phase II trials in autoimmune and inflammatory conditions.
#Biotechnology